Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of ARX201 in young adults with childhood-onset growth hormone deficiency
2007-001746-40Phase 2Completed
- Sponsor
- Ambrx
- Start
- Apr 2007
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of ARX201 in growth hormone deficiency (GHD) (3 arms), sponsored by Ambrx. Primary endpoints: Primary safety and tolerability endpoint and Primary pharmacodynamic endpoint. Started Apr 2007; status: completed.
02
Drugs
ARX201
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2007-001746-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001746-40.